Literature DB >> 1731795

A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene.

K Sugita1, H Yoshida, M Matsumoto, S Matsutani.   

Abstract

A novel compound, depudecin, induced production of the flat phenotype of Ki-ras-transformed NIH3T3 cells at the low concentration of 1 microgram/ml. This effect was reversible. Actin stress fiber was detected in these cells after depudecin treatment. Almost complete reversion to the flat phenotype was observed at 6 h after depudecin addition. The synthesis of ras-mRNA did not decrease enough with depudecin treatment at the concentration of 10 micrograms/ml to reverse the transformed morphology.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731795     DOI: 10.1016/s0006-291x(05)80156-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Discovery of novel drug targets and their functions using phenotypic screening of natural products.

Authors:  Junghwa Chang; Ho Jeong Kwon
Journal:  J Ind Microbiol Biotechnol       Date:  2015-09-12       Impact factor: 3.346

2.  Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.

Authors:  H J Kwon; T Owa; C A Hassig; J Shimada; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

3.  A novel styryl diphenylamine derivative reverts the transformed phenotype of human fibrosarcoma HT1080 cells.

Authors:  I Ohizumi; M Tanemura; S Kaihoh
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

Review 4.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases.

Authors:  Elizabeth E Hull; McKale R Montgomery; Kathryn J Leyva
Journal:  Biomed Res Int       Date:  2016-07-31       Impact factor: 3.411

5.  Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor.

Authors:  H Tanaka; K Nishida; K Sugita; T Yoshioka
Journal:  Jpn J Cancer Res       Date:  1999-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.